Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.

Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

Key Takeaways A patient died from liver injury while taking the gene therapy ElevidysSarepta says more than 800 patients have ...

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

The plan put forth Tuesday could see the Sackler family pay up to $7 billion. Also in the news: Merck prepares to close its manufacturing plant in Pennsylvania; Optum Rx, which includes UnitedHealth ...

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...

Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%. The young man died of acute ...